Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Knightscope
Sponsored
content by Knightscope
MA
MarketJar
Community Contributor
The Next Phase of Defense AI: A Robotic Response to America’s Security Gaps
Autonomous systems are no longer just a futuristic vision — they’re fast becoming an essential layer of national security. As AI reshapes everything from finance to warfare, physical security remains one of the most under-addressed frontiers.
View narrative
US$12.00
FV
54.3% undervalued
intrinsic discount
22.00%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
1
users have commented on this narrative
15
users have followed this narrative
New
narrative
Figma
TI
TickerTickle
Community Contributor
Figma (FIG): The S&P 500’s Design Standard Turning Into an All-in-One Platform
Watching Figma Grow Up I’ve been using Figma almost every single day for the past five years. As a product designer, it’s been my main tool for designing interfaces, testing and prototyping ideas, and also for working together with teams in different countries and time zones.
View narrative
US$65.70
FV
7.2% overvalued
intrinsic discount
30.00%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
Updated
narrative
Sleep Cycle
MA
Mandelman
Community Contributor
Sleep Cycle's Revenue Set to Rise 10% with Strong Revenue Model
Update Q1 2025 (updated 250510) The latest user‐growth data suggest headwinds for top-line revenue, but management’s active repricing initiatives should help offset this. By combining modest user gains with targeted price increases, the company can still drive overall revenue growth.
View narrative
SEK 38.04
FV
25.3% undervalued
intrinsic discount
3.15%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
23
users have followed this narrative
Updated
narrative
JB Hi-Fi
RO
Robbo
Community Contributor
Has JB Hi-Fi Lost Its Point of Difference?
I may be showing my age here, but I feel that a decade or so ago, shopping at JB Hi-Fi was a different experience. There seemed to be a deliberate policy of employing sales staff from alternative subcultures, which gave the stores a unique, edgy vibe.
View narrative
AU$76.00
FV
51.4% overvalued
intrinsic discount
-0.45%
Revenue growth p.a.
Set Fair Value
3
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Ibotta
AN
AnalystLowTarget
Consensus Narrative from 7 Analysts
Rising Privacy Regulations Will Crush Digital Ad Prospects
Key Takeaways Intensifying regulatory pressures and shifting brand loyalty trends threaten Ibotta's advertiser base, constraining revenue growth and margin improvement. Rising competition from retailer programs and high technology spend limit Ibotta's ability to improve earnings, with organizational upheaval heightening sales and client retention risks.
View narrative
US$24.00
FV
7.5% overvalued
intrinsic discount
-2.32%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
Adient
AN
AnalystLowTarget
Consensus Narrative from 11 Analysts
Rising Regulatory Costs Will Erode Margins Despite US Wins
Key Takeaways Shifting industry trends and regulatory pressures threaten Adient's core market while increasing costs and dampening revenue growth prospects. Industry consolidation and OEMs' move to in-house production weaken Adient's bargaining power and customer base, pressuring margins and profitability.
View narrative
US$17.00
FV
47.3% overvalued
intrinsic discount
0.39%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
Tronox Holdings
AN
AnalystLowTarget
Consensus Narrative from 8 Analysts
Rising Compliance Costs And Fierce Chinese Competition Will Hamper Margins
Key Takeaways Increasing regulatory and environmental pressures, along with sustained demand shifts, threaten long-term profitability and revenue stability for Tronox. High debt levels and exposure to industry overcapacity amplify financial risks, constraining future growth and flexibility.
View narrative
US$1.11
FV
282.4% overvalued
intrinsic discount
-0.013%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
Mankind Pharma
AN
AnalystHighTarget
Consensus Narrative from 17 Analysts
India's Rising Middle Class And Urbanization Will Reshape Healthcare Markets
Key Takeaways Strong specialty biologics portfolio, innovative pipeline, and rapid execution position the company for accelerated margin and earnings growth ahead of consensus expectations. Expanding distribution, premium consumer brands, and robust R&D create a structural edge to capitalize on rising healthcare demand and chronic disease prevalence.
View narrative
₹3.30k
FV
24.2% undervalued
intrinsic discount
16.35%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
Aspen Aerogels
AN
AnalystLowTarget
Consensus Narrative from 6 Analysts
Rising Regulation And Capital Strains Will Weaken EV Outlook
Key Takeaways Revenue growth and profitability are threatened by regulatory uncertainty, reduced demand in core markets, and rising compliance and input costs. Sustained cash flow pressures and intensifying competition create risks of margin compression, asset dependency, and diminished market diversification.
View narrative
US$6.00
FV
15.5% overvalued
intrinsic discount
0.69%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
Edgewell Personal Care
AN
AnalystLowTarget
Consensus Narrative from 7 Analysts
Legacy Brand Erosion Will Pressure Margins Despite Isolated Gains
Key Takeaways Shifting consumer preferences and rising competition threaten core brands and margins, increasing pressure on Edgewell's innovation, pricing, and market positioning. Operational cost pressures, restructuring challenges, and weak non-core innovation undermine profit growth, financial flexibility, and shareholder returns.
View narrative
US$21.00
FV
11.9% overvalued
intrinsic discount
1.52%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
Cheesecake Factory
AN
AnalystLowTarget
Consensus Narrative from 17 Analysts
Overvaluation And Rising Costs Will Threaten Dine-In Traffic
Key Takeaways Persistent cost pressures and shifting consumer preferences threaten profitability and necessitate costly menu innovation to maintain brand relevance. Limited expansion capability and increased competition from more adaptable concepts restrain growth and earnings potential.
View narrative
US$50.41
FV
22.2% overvalued
intrinsic discount
5.65%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
6 days ago
author updated this narrative
Oddity Tech
AN
AnalystLowTarget
Consensus Narrative from 9 Analysts
Inflation And Privacy Laws Will Hurt AI But Enable Adaptation
Key Takeaways Stricter privacy laws, rising costs, and shifting consumer sentiment threaten Oddity Tech's AI-powered model, potentially reducing margins and hindering growth. Increased investment needs, regulatory risks, and intensifying competition challenge Oddity's ability to profitably expand and defend its digital-only business.
View narrative
US$55.00
FV
8.4% overvalued
intrinsic discount
18.07%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
6 days ago
author updated this narrative
OMV
AN
AnalystHighTarget
Consensus Narrative from 15 Analysts
European Urbanization And Green Hydrogen Will Expand Decarbonization Opportunities
Key Takeaways Strategic growth in Chemicals, structural cost advantages, and overlooked synergy potential position OMV for outperformance on revenue, margins, and future earnings power. Early moves in green hydrogen, renewables, and untapped exploration projects enhance OMV's long-term value, cash flows, and shareholder returns beyond market forecasts.
View narrative
€62.50
FV
22.6% undervalued
intrinsic discount
3.92%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
Value any company in seconds
Popular companies